Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025
MIAMI, Feb. 14, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the Emerging Growth Virtual Conference taking place February 18-19, 2025.
Details for the Company’s presentation:
| Date: | February 19, 2025 |
| Time: | 3:10 – 3:20 p.m. ET |
The webcast for this conference presentation may be accessed at the “” section of the Company’s website. A replay of the webcast will be available on the Longeveron website for 180 days following the conference.
Questions may be submitted in advance to or asked during the event.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-BTM development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit or follow Longeveron on , , and .
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
